The relevance of these findings is underscored by recent results driven from phase 2 clinical trials testing the CFTR potentiator VX-770 [12] and the CFTR corrector PTC124 [15] in CF patients carrying CFTR mutations responsive to these drugs. This evidence concerns the gene CFTR and cystic fibrosis.